Ingelheim, Germany, and San Francisco, Calif., June 10, 2025 | Boehringer Ingelheim, a global leader in animal health, and Eko Health, a pioneer in applying artificial intelligence (AI) for early ...

FibroScan ®, Echosens' non-invasive liver assessment technology, has played a critical role in Boehringer Ingelheim's liver disease research and continues to support two ongoing Survodutide Phase ...

Boehringer Ingelheim has launched its poultry vaccine in India—a single-dose, next-generation solution that protects against Bursal, Newcastle and Marek’s disease, the company said. This ...

PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure-affecting more than 250 ...

That's changing. Employees from Boehringer Ingelheim, Argentina are collaborating with La Higuera, a non-profit organization committed to delivering primary healthcare services to rural communities.

The Lung Cancer Research Foundation (LCRF) announces today a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer ...

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim, one of the world's leading ...

Abu Dhabi strengthens global pharma vision with Boehringer Ingelheim partnership New MoU positions UAE as rising global hub for pharmaceutical innovation Last updated: June 18, 2025 | 15:18 ...

The study, supported by Boehringer Ingelheim, included 4,000 patients from Geisinger with diabetes and/or hypertension, two prominent risk factors for CKD. Patients in the pilot group received ...

The LCRF|Boehringer Ingelheim Team Science Award on Innovative Approaches Toward the Treatment of HER2-Driven Lung Cancer award, is a $1.5 million, three-year award to a team of researchers whose ...

Daniel Ghinn discusses the possible positive outcomes to Boehringer Ingelheim’s Syrum, the highly-anticipated pharmaceutical social game, ahead of its launch this week. Ever since Boehringer ...

In addition to schizophrenia, both Autifony and Boehringer Ingelheim want to explore the Kv3.1/3.2 mechanism for other indications, including hearing disorders and orphan CNS disorders, such as ...